Top ten stories in the pharmaceutical industry this week
pharmafile | September 9, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. From one of the industry’s biggest players saying goodbye to its long-serving CEO to some rather baffling regulatory decisions, it’s been another busy week.
10. ABPI welcomes Roche back into the fold eight years after suspension
Roche was initially suspended for ethical breaches in 2008, and then refused an offer of readmission in 2009.
9. Lars Rebien Sørensen to retire as CEO of Novo Nordisk
Lars Fruergaard Jørgensen appointed as his successor, effective 1 January.
8. Teva suffers EpiPen generic setback after FDA rejection
The news is a real boost for Mylan whose sales of EpiPen were expected to suffer when the new drug became available in 2017.
7. Celgene and Agios to file FDA application for “first-in-class” cancer drug
The new drug application will be based on an ongoing Phase I/II study of patients with relapsed or refractory acute myeloid leukaemia
6. Eisai “cannot understand” German agency’s recommendation to reject Halaven
Compelling Phase III data has been ignored by the German’s equivalent of NICE, according to Eisai.
5. Cloud on the horizon: Cloud computing and the clinical trial
With clinical trials becoming increasingly unfeasible as financial costs and time expenses rise, Matt Fellows investigates how cloud computing may just be the answer the industry is looking for.
4. European Commission approves new RA treatment from BMS
Bristol-Myers Squibb’s Orencia (abatacept) is the first biologic with a specific EU indication for the treatment of methotrexate-naïve rheumatoid arthritis patients.
3. GSK announce positive results for chronic obstructive pulmonary disease treatment
The drug saw a reduction in the rate of moderate or severe exacerbations compared with ‘usual care.’
2. AZ’s first respiratory biologic meets primary endpoints in Phase III trials
Results presented at the European Respiratory Society international congress shows the potential of benralizumab to be added to standard-of-care severe asthma treatment.
1. Up to 120 jobs set to go as Novartis closes down Cell and Gene Therapies unit
The company confirmed that it will integrate its operations into the broader organisation.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
